EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Oncogenic driver and therapeutic target: Prolactin signalling axis in retroperitoneal sarcoma

Fu'an Xie, Lingwei Gu, Kunrong Yang, Shuai Wang iD, Mengmeng Xiao, Guangting Yan, Quan Zhang, Rubing Liang, Aobo Zhuang, Zhe Xi, Yujia Niu, Yanhua Chen und 10 weitere

Clinical and Translational Medicine · 2026-05 · 16 (5)

DOI: 10.1002/ctm2.70669 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, online erschienen am 05.05.2026. Verfasst von Fu'an Xie und 21 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Center, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China. Hauptthemen laut MEDLINE: Retroperitoneal Neoplasms, Signal Transduction, Prolactin, Sarcoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Xiamen Medical Industry Combined Guidance Project, NIEHS NIH HHS, Key Project Funding on Social Development of Fujian Province of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Retroperitoneal sarcoma (RPS) is a type of malignant tumour arising from mesenchymal tissues within the retroperitoneal space. RPSs tend to develop covertly and are often undiscovered when they have already grown significantly and invaded surrounding tissues and organs. These malignancies demonstrate high recurrence rates, present surgical challenges and exhibit limited responsiveness to radiotherapy and chemotherapy. Serum‐derived molecules are known to play critical roles in tumourigenesis and tumour progression. However, the serum molecular profile of RPS patients remains unclear.

Methods

We performed multi‐omics analysis of serum samples from patients with retroperitoneal dedifferentiated liposarcoma. Prolactin concentrations were quantified using Enzyme‐Linked Immunosorbent Assay (ELISA). RNA‐seq facilitated the identification of candidate signalling pathways, while gene expression was validated through quantitative polymerase chain reaction, immunohistochemistry and western blot analyses. Molecular mechanisms underlying transcriptional regulation were investigated through Chromatin Immunoprecipitation‐qPCR (ChIP‐qPCR) and dual‐luciferase reporter gene assays.

Results

Integrative multi‐omics profiling identified significant perturbations in galactose metabolism coupled with marked elevation of prolactin (PRL) levels in Retroperitoneal Liposarcoma (RLPS) patients. Further screening of serum prolactin levels in 100 patients with retroperitoneal tumours revealed that 90% of the cases exhibited hyperprolactinaemia in our research cohort, encompassing both malignant sarcomas and benign tumours. Studies at the clinical sample, cellular and animal levels have found that abnormally elevated prolactin in the serum can originate from sarcoma tissues. Mechanistic investigations identified SRY‐box transcription factor 4 (SOX4) as a previously unrecognised transcriptional regulator of PRL. Functionally, PRL not only enhanced liposarcoma cell and fibrosarcoma cell proliferation but also conferred resistance to MDM2 inhibitors. Signalling pathway analysis revealed that PRL activates the Janus Kinase–Signal Transducer and Activator of Transcription Pathway (JAK–STAT) signalling pathway and up‐regulates c‐MYC expression.

Conclusions

This study indicates that PRL can serve as an oncogenic driver and therapeutic target. The identification of SOX4–PRL–c‐MYC signalling axis provides actionable insights for developing novel therapeutic strategies against this malignancy. Key points Retroperitoneal sarcoma cells can secrete prolactin into the bloodstream, inducing hyperprolactinaemia, which subsequently triggers metabolic reprogramming, such as glucose metabolism. SOX4 can function as a transcription factor that facilitates PRL transcription. PRL can activate the JAK–STAT signalling pathway by binding to PRLR on sarcoma cells, leading to the up‐regulation of c‐MYC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Retroperitoneal NeoplasmsSignal TransductionProlactinSarcomaLiposarcomaHumansFemaleAnimalsMaleMiddle AgedAged

Stichwörter der Autor:innen

SOX4c‐MYChyperprolactinaemialactoseprolactinretroperitoneal sarcoma

Substanzen

Prolactin

Autor:innen und Institutionen

  • Cancer Research Center, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China.
  • National Institute for Data Science in Health and Medicine, Xiamen University, Xiamen, Fujian, China.
  • Xiamen University Research Center of Retroperitoneal Tumor Committee of Oncology Society of Chinese Medical Association, Xiamen University, Xiamen, Fujian, China.
  • Xiamen Treatgut Biotechnology Co., Ltd., Xiamen, Fujian, China.
  • Laboratory of Biochemistry and Molecular Biology Research, Department of Clinical Laboratory, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hosptial, Fuzhou, Fujian, China.
  • Department of Cardiology, Xiamen Key Laboratory of Cardiac Electrophysiology, Xiamen Institute of Cardiovascular Diseases, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiame…

ORCID-Profile: Shuai Wang, Ting Wu, Chenghua Luo, Lanlan Lian, Wengang Li

Förderung

  • Xiamen Medical Industry Combined Guidance Project
  • NIEHS NIH HHS
  • Key Project Funding on Social Development of Fujian Province of China
  • Startup Fund for Scientific Research, Fujian Medical University
  • Postdoctoral Fellowship Program of CPSF
  • National Natural Science Foundation of China
  • Joint Research Center of School of Medicine, Xiamen University-Jiangsu Charity Biotech Co., Ltd
  • Young Elite Scientists Sponsorship Program by CAST

Zitieren

APA

Xie, F., Gu, L., Yang, K., Wang, S., Xiao, M., Yan, G., Zhang, Q., Liang, R., Zhuang, A., Xi, Z., Niu, Y., Chen, Y., Xia, X., Qu, L., Zhao, B., Li, W., Wu, T., Yu, C., Luo, C., …, & Li, W. (2026). Oncogenic driver and therapeutic target: Prolactin signalling axis in retroperitoneal sarcoma. Clinical and Translational Medicine, 16(5). https://doi.org/10.1002/ctm2.70669

Vancouver

Xie F, Gu L, Yang K, Wang S, Xiao M, Yan G, et al. Oncogenic driver and therapeutic target: Prolactin signalling axis in retroperitoneal sarcoma. Clinical and Translational Medicine. 2026;16(5). doi:10.1002/ctm2.70669

BibTeX
@article{Xie2026,
  author = {Xie, Fu'an and Gu, Lingwei and Yang, Kunrong and Wang, Shuai and Xiao, Mengmeng and Yan, Guangting and Zhang, Quan and Liang, Rubing and Zhuang, Aobo and Xi, Zhe and Niu, Yujia and Chen, Yanhua and Xia, Xiaogang and Qu, Linlin and Zhao, Bin and Li, Weibing and Wu, Ting and Yu, Chundong and Luo, Chenghua and Wang, Houzhao and Lian, Lanlan and Li, Wengang},
  title = {Oncogenic driver and therapeutic target: Prolactin signalling axis in retroperitoneal sarcoma},
  journal = {Clinical and Translational Medicine},
  year = {2026},
  volume = {16},
  number = {5},
  doi = {10.1002/ctm2.70669}
}
Kostenlos starten →